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Abstract
Background: Although smokeless tobacco (ST) use has played a major role in the low smoking
prevalence among Swedish men, there is little information at the population level about ST as a
smoking cessation aid in the U.S.
Methods: We used the 2000 National Health Interview Survey to derive population estimates for
the number of smokers who had tried twelve methods in their most recent quit attempt, and for
the numbers and proportions who were former or current smokers at the time of the survey.
Results: An estimated 359,000 men switched to smokeless tobacco in their most recent quit
attempt. This method had the highest proportion of successes among those attempting it (73%),
representing 261,000 successful quitters (switchers). In comparison, the nicotine patch was used
by an estimated 2.9 million men in their most recent quit attempt, and almost one million (35%)
were former smokers at the time of the survey. Of the 964,000 men using nicotine gum, about
323,000 (34%) became former smokers. Of the 98,000 men who used the nicotine inhaler, 27,000
quit successfully (28%). None of the estimated 14,000 men who tried the nicotine nasal spray
became former smokers.
Forty-two percent of switchers also reported quitting smoking all at once, which was higher than
among former smokers who used medications (8–19%). Although 40% of switchers quit smoking
less than 5 years before the survey, 21% quit over 20 years earlier. Forty-six percent of switchers
were current ST users at the time of the survey.
Conclusion: Switching to ST compares very favorably with pharmaceutical nicotine as a quit-
smoking aid among American men, despite the fact that few smokers know that the switch provides
almost all of the health benefits of complete tobacco abstinence. The results of this study show that
tobacco harm reduction is a viable cessation option for American smokers.
Background
For the past half century men in Sweden have had among
the lowest rates of smoking – and the lowest rates of
smoking-related illnesses – in the developed world [1].
Several recent studies have shown that the high prevalence
of smokeless tobacco (ST) use among Swedish men has
played a substantial role in the remarkably low smoking
prevalence, mainly in two ways. First, the popularity of ST
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among Swedish men suppresses smoking initiation [2-4].
More importantly, substituting ST facilitates risk reduc-
tion by allowing smokers to become smoke-free without
abstaining from tobacco and nicotine altogether [3-6], but
complete abstinence is still achievable [4,7]. There is now
evidence that ST use has started to become popular among
Swedish women as well, with similar effects on smoking
rates [4,8]. Tobacco harm reduction, which actively
encourages inveterate smokers to switch to safer sources of
nicotine including ST, is increasingly seen as a promising
public health intervention [9-11].
Like Sweden, the U.S. is one of the few Western countries
with measurable ST use. According to the National Health
Interview Survey (NHIS), the prevalence of ST use among
men in the U.S. was 4.5% in the year 2000 [12]. However,
in contrast to Sweden, there are only anecdotal reports of
ST use for smoking cessation in the U.S [13]. In fact, few
resources provide information about cessation at the pop-
ulation level, especially with respect to ST use.
One recent article briefly mentioned that the 2000 NHIS
collected information on ST use as a quit-smoking
method [14]. However, the information in that article was
very selective (1.2% of male former smokers age 36–47
years had switched to snuff or chewing tobacco in order to
quit smoking), and it provided little perspective on how
switching to ST compared with other cessation methods.
In fact, the 2000 NHIS collected information on 12 meth-
ods used by smokers in their most recent quit attempt and
who subsequently either quit smoking successfully
(former smokers at the time of the survey) or had failed to
quit (current smokers). This study uses that survey to esti-
mate the number of male smokers in the U.S. that used
various cessation methods.
Methods
We obtained the 2000 NHIS Adult Sample and Cancer
Control Module data files from the Inter-University Con-
sortium for Political and Social Research [15]. Our study
focused mainly on men, because in 2000 the prevalence
of ST use among women was too low (0.3%)[12] to pro-
vide reliable information. However, we generated point
estimates of switching to ST among women for compari-
son.
Subjects who had smoked ≥ 100 cigarettes in their lifetime
and who smoked every day or some days were classified as
current smokers, while subjects who had smoked ≥ 100
cigarettes in their lifetime and who did not currently
smoke were classified as former smokers [16]. Subjects
who had used chewing tobacco or snuff 20 times in their
life and who used either tobacco product every day or
some days were classified as current smokeless tobacco
users, while subjects who had used either product 20
times in their life and who did not currently use ST were
classified as former users [12]. The cancer control module
also asked subjects if they had ever used chewing tobacco
or snuff.
In the cancer control module, 3,622 male current smokers
were asked: "Have you ever stopped smoking for one day
or longer because you were trying to quit smoking?"
Those answering "no" (n = 1,325, 37%) were excluded
from further analysis regarding cessation attempts. The
remaining 2,297 smokers were asked: "The last time you
stopped smoking, which of these methods did you use?"
Subjects were prompted to "mark all [of the following
methods] that apply": (1) stopped all at once (cold tur-
key), (2) gradually decreased the number of cigarettes
smoked in a day, (3) instructions in a pamphlet or book,
(4) one-on-one counseling, (5) stop-smoking clinic or
program, (6) nicotine patch, (7) nicotine containing gum
(such as Nicorette), (8) nicotine nasal spray, (9) nicotine
inhaler, (10) Zyban/Bupropion/Wellbutrin medication
(abbreviated bupropion here), (11) switched to chewing
tobacco or snuff (ST here), and (12) any other method.
Information about methods was obtained from 2,180
(95%) of the current smokers who had ever tried to quit.
In similar fashion, 3,653 former smokers were asked:
"When you stopped smoking completely, which of these
methods did you use?" followed by the same choices.
Information about methods was obtained from 3,548
former smokers (98%).
We identified the quit methods that are endorsed in the
Clinical Practice Guideline (CPG) from the Public Health
Service, U.S. Department of Health and Human Services
[17]. The survey asked former smokers how long ago they
had quit, and we classified these subjects into four groups
based on the number of years since quitting: 0–4, 5–14,
15–19 and 20+. Because subjects could select more than
one method, the results reported here are not mutually
exclusive.
The 2000 NHIS employed a complex design involving
stratification, clustering and multistage sampling. We
used SPSS statistical software with Complex Samples (Ver-
sion 15.0 for Windows) to provide estimates, based on the
non-institutionalized civilian population of the U.S, of
the quit-smoking methods used by the 24.0 million men
who had successfully quit smoking (former smokers), and
by the 15.1 million men who had attempted to quit but
were unsuccessful on their last attempt (current smokers).
Results
Table 1 provides the number of male survey respondents
who had used various methods in their most recent quit
attempt and the percentages who were former and currentHarm Reduction Journal 2008, 5:18 http://www.harmreductionjournal.com/content/5/1/18
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smokers at the time of the survey. An estimated 33 million
men reported stopping all at once in their most recent quit
attempt; almost 21 million (64%) were former smokers at
the time of the survey. Of the 2.9 million men who tried
to gradually decrease the number of cigarettes that they
smoked, 1.3 million (45%) had become former smokers.
Of the 76,000 men following instructions in a pamphlet
or book, 28% (21,000) became former smokers.
An estimated 359,000 men switched to ST in their most
recent quit attempt, and 73% of them (261,000) were
former smokers. In comparison, only 42,000 women
switched to ST in their most recent quit attempt, and only
38% of them (16,000) were former smokers at the time of
the survey.
Among CPG-endorsed methods, the nicotine patch was
used by the largest number of men (estimate, 2.9 million)
in their most recent quit attempt, and almost 1 million
(35%) were former smokers at the time of the survey. An
estimated 1.1 million men used bupropion, and 308,000
(29%) were former smokers. Of the 964,000 men using
nicotine gum in their most recent quit attempt, about
323,000 (34%) became former smokers. A stop-smoking
clinic/program was used by an estimated 311,000 men,
50% of whom (155,000) became former smokers, the
highest proportion among CPG-endorsed methods. Of
the estimated 107,000 men who used one-on-one coun-
seling, 45,000 became former smokers (43%). Of the
98,000 men who used the nicotine inhaler in their most
recent quit attempt, 27,000 quit successfully (28%). None
of the estimated 14,000 men who used the nicotine nasal
spray became former smokers. An estimated 1.3 million
men used other, unspecified methods in their most recent
quit attempt, and 817,000 (63%) became former smok-
ers.
We conducted additional analyses restricted to male
former smokers who had quit by using the nicotine patch,
nicotine gum, bupropion or by switching to ST (hereafter
referred to as switchers), in order to provide a better com-
parison of these methods. For clarity, we use actual survey
numbers and unweighted proportions when reporting
these findings. Table 2 provides more information about
the use of multiple methods by former smokers who quit
by using the three medications or ST. Exclusive use of a
single method was more common among patch (70%)
and bupropion (64%) users than among gum users or
switchers (55%). Forty-two percent of switchers also
reported stopping all at once, which was higher than for
bupropion (8%), nicotine patch (18%) or nicotine gum
(19%). Fifteen percent of switchers reported gradually
decreasing the number smoked, which was somewhat
higher than for bupropion (3%) or the patch (4%). Mul-
tiple medication use was more frequent in former smok-
ers who used gum (26%) or bupropion (21%), compared
with former smokers who used the patch (10%).
Table 3 shows the distribution of former smokers who
used medications or switched to ST, according to the
number of years since quitting. Ninety-five percent of
bupropion users quit from 0 to 4 years before the survey,
Table 1: Number of male smokers who had tried various methods in their last quit attempt, and the proportions (%) who were former 
and current smokers at the time of the survey, NHIS 2000
Method Survey Count^ U.S. Population Estimate^* % Former (95% CI) % Current (95% CI)
Stopped all at once 4,822 32,589,195 64 (63–66) 36 (34–37)
Gradually decreased cigarettes smoked 426 2,888,019 45 (40–51) 55 (49–61)
Switched to ST 43 358,668 73 (55–86) 27 (14–45)
Pamphlet/book 11 75,522 28 (9–61) 72 (39–91)
CPG Endorsed
Nicotine patch 393 2,881,084 35 (29–40) 65 (60–71)
Bupropion 138 1,059,982 29 (21–38) 71 (62–79)
Nicotine gum 129 963,692 34 (25–44) 66 (56–75)
Clinic/program 42 310,938 50 (33–67) 50 (33–67)
One-on-one counseling 19 106,501 43 (23–64) 57 (36–77)
Nicotine inhaler 13 98,124 28 (9–61) 72 (39–91)
Nicotine nasal spray 3 14,463 0 (0–35)+ 100 (65–100)+
Any other method 182 1,295,707 63 (54–71) 37 (29–46)
^ Column total exceeds the number of current and former smokers because subjects chose multiple methods.
* Population estimates are reported to the last digit to aid in re-analysis of results. They are not intended to imply a level of precision beyond what 
can be achieved from the survey.
+ CI is an approximation based on the unweighted survey count.
CI – confidence interval.
ST – smokeless tobacco.
CPG – Clinical Practice Guideline, Department of Health and Human Services.Harm Reduction Journal 2008, 5:18 http://www.harmreductionjournal.com/content/5/1/18
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while 87% of patch users quit up to 9 years prior to the
survey. Although 47% of gum users quit 0–4 years before
the survey, the remainder were distributed across the
other timeframes, including 20+ years. This pattern was
even more evident for switchers, 21% of whom had
become former smokers 20+ years prior to the survey.
Because separate sets of survey questions were devoted to
smoking cessation and smokeless tobacco use, we were
able to obtain information about the latter on the 33
switchers. Fifteen of them (46%) were current ST users at
the time of the survey, and twelve (36%) were former
users. Of the six that were classified as never users, 3
answered yes to the question about ever use of chewing
tobacco or snuff.
Discussion
Anecdotal reports have shown that individual smokers
have quit smoking by switching to ST [13]. However, this
study provides evidence from a nationally representative
survey that switching to ST is a viable, although infre-
quently attempted, quit smoking method for men in the
U.S. Of the 261,000 men who switched to ST and became
former smokers, about 120,000 (46%) were current ST
users at the time of the survey, indicating that the switch
may be permanent for some. On the other hand, 54% of
switchers did not use any tobacco product at the time of
the survey, suggesting that switching to ST is not incom-
patible with a goal of achieving complete nicotine and
tobacco abstinence.
This study shows that switching to ST resulted in over
twice the proportion of former smokers (73%) than the
nicotine patch (35%), gum (34%), inhaler (28%) or nasal
spray (0%). It is important to note that these percentages
do not mean that switching to ST is successful 73% of the
time or that using pharmaceutical products have a 30%
success rate. This type of study cannot answer the question
"How often does a particular method work when tried by
a particular individual?" The percentages reported for var-
ious methods in our study may be substantially different
from corresponding answers to this question. The main
reason for the distinction is that the NHIS only collected
information about the most recent method used. It has no
information on the methods used in previous failed quit
attempts, or how many times each method was tried.
Table 2: Male former smokers who used medications or switched to ST, and their distribution (%) according to other methods used.
Method Nicotine Patch (n = 128) Nicotine Gum (n = 42) Bupropion (n = 39) Switched to ST (n = 33)
Stopped all at once 18% 19% 8% 42%
Gradually decreased cigarettes smoked 4 10 3 15
Switched to ST 1 5 0 55*
Pamphlet/book 2 5 0 3
Nicotine patch 70* 19 13 3
Bupropion 4 7 64* 0
Nicotine gum 6 55* 8 6
Clinic/program 2 0 0 0
One-on-one counseling 0 0 3 0
Nicotine inhaler 2 2 0 0
Nicotine nasal spray 0 0 0 0
Any other method 1 5 10 3
* Percentage of subjects using only that method.
n – unweighted survey count.
ST – smokeless tobacco.
Note: Column percentages total over 100% because some subjects used multiple methods.
Table 3: Male former smokers who used medications or switched to ST, and their distribution (%) according to the number of years 
since quitting.
Years Since Quitting Nicotine Patch (n = 128) Nicotine Gum (n = 42) Bupropion (n = 39) Switched to ST (n = 33)
0–4 60% 47% 95% 40%
5–9 27 14 0 12
10–14 11 17 0 18
15–19 1 17 0 9
20+ 1 5 5 21
n – unweighted survey count.
ST – smokeless tobaccoHarm Reduction Journal 2008, 5:18 http://www.harmreductionjournal.com/content/5/1/18
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Regardless of how one interprets the proportions of
former and current smokers, it is particularly striking that
an estimated 359,000 smokers tried to stop smoking by
switching to ST – and over a quarter of a million became
former smokers – especially since Americans are largely
misinformed about the health risks of ST use [1,18]. For
example, in 2005 a survey of 2,028 adult U.S. smokers
found that only 11% correctly believed that ST products
are less hazardous than cigarettes [19]. In another survey,
82% of U.S. smokers incorrectly believed that chewing
tobacco is just as likely to cause cancer as smoking ciga-
rettes [20]. These findings are in direct contrast to the gen-
eral agreement among tobacco research and policy experts
that ST use is far less hazardous than smoking. Although
estimates are not precise, ST use likely confers only 0.1%
to 10% of the risks of smoking [21-23].
It is safe to assume that rates of switching would increase
substantially if smokers knew that switching to ST
achieves almost all of the health benefits as quitting
tobacco and nicotine altogether [1]. In 2000 the most
likely beneficiaries of this knowledge would have been the
1.1 million American men who were dual users of both
cigarettes and ST products. These men were already com-
fortable consuming nicotine from both combusted and
smoke-free tobacco. With the knowledge that ST products
were 100 times less hazardous than cigarettes, it is con-
ceivable that most would have chosen exclusive use of ST,
resulting in a decline of 1.2 percentage points in national
adult male smoking prevalence.
Comparison of ST and pharmaceutical nicotine in a regu-
latory, legal and social context further suggests that the
potential of ST as a cessation aid has been under-realized.
Nicotine gum and the nicotine patch have been available
since 1984 and 1992 respectively [24], and both achieved
non-prescription status in 1996, when the manufacturer
conducted a large promotional campaign in conjunction
with the American Cancer Society Great American
Smokeout [25]. In 1999 an estimated $200 million was
spent on print and broadcast advertising for smoking ces-
sation products [26].
In contrast to the heavy promotion and advertising of
pharmaceutical nicotine products for smoking cessation
in the late 1990s, the environment for ST products was
quite negative. A ban on broadcast advertising of ST had
been established as early as 1986 [27], so the estimated
$170 million spent by manufacturers in 1999 was
restricted largely to print media and other forms of adver-
tising and promotion [28]. Not only were manufacturers
effectively prohibited from offering ST products as
reduced-risk options for smokers, a counter-marketing
program was launched by congressional legislation in
1986, in the form of a mandatory warning on every third
package of ST sold in the U.S.: "This product is not a safe
alternative to cigarettes" [27]. In addition, major efforts
have been made by the American tobacco control com-
munity to impede any widespread transition from ciga-
rettes to ST [1,18]. Despite the pro-pharmaceutical and
anti-ST climate, an estimated 261,000 men had used
smokeless tobacco to quit smoking by the year 2000.
While this number is lower than the number who had suc-
cessfully used the nicotine patch (about one million), it is
comparable to the number who had successfully used
either nicotine gum or antidepressants, and far more than
the number who were successful with other pharmaceuti-
cal nicotine products.
We expected to find evidence in later surveys that increas-
ing awareness of the low risk profile of modern, socially
acceptable ST products would have resulted in heightened
popularity for this cessation method. Unfortunately, no
information on switching to ST is available in subsequent
NHIS surveys, because that option was removed when the
Cancer Control module appeared again in the 2005 NHIS
[29]. It is possible that individuals responsible for design-
ing the module expected an increase in switching as well,
and that they chose to not find out.
A major strength of this study is that it is based on the sur-
vey series that the Centers for Disease Control and Preven-
tion (CDC) uses for national smoking prevalence
estimates [16]. In fact, our findings were produced from
the very same dataset (and specific survey questions) used
by the American Cancer Society in a recent study of smok-
ing cessation treatments used by American smokers [30].
Thus, we were surprised when a senior Cancer Society sci-
entist, who was a coauthor on that study [30], stated
emphatically that "There is no evidence that smokers will
switch to ST products and give up smoking" [31].
Although the Cancer Society has not endorsed tobacco
harm reduction, its scientists certainly know that there is
unequivocal evidence from the 2000 NHIS survey that
261,000 smokers have switched to ST products in order to
quit smoking.
Studies based on survey data are limited by the nature of
the survey instrument and the quality of self-reported
information. With respect to this survey, current and
former smokers were encouraged to choose multiple
methods that were not mutually exclusive, which creates
some difficulty in reporting the results and may be confus-
ing for some readers. For example, "Stopped all at once
(cold turkey)" was so frequently chosen (with or without
other methods) – as would be expected – that all other
methods pale in direct comparison. That comparison is
certainly confusing, but it may also be inappropriate,
since the cold turkey response is orthogonal to the other
methods. However, excluding this item would have elim-Harm Reduction Journal 2008, 5:18 http://www.harmreductionjournal.com/content/5/1/18
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inated information that some readers consider useful. Our
goal was to present a complete picture of the data, includ-
ing how frequently all of the methods were chosen.
We noted some inconsistencies among former smokers
using medications and switching to ST. For example,
among the 128 former smokers who used the nicotine
patch, 16 reported that they quit before the patch became
available. Two subjects using nicotine gum and two using
bupropion had similar inconsistencies. In addition, for
three subjects who switched to ST, their responses to other
questions indicated no ST use. It is not possible to resolve
these irregularities in a systematic manner, but they may
affect the certainty of the estimates.
Conclusion
This study documents that switching to ST compares very
favorably with pharmaceutical nicotine as a quit-smoking
aid among American men, despite the fact that few smok-
ers know that the switch provides almost all of the health
benefits of complete tobacco abstinence. As long as Amer-
ican smokers are misinformed about the comparative
risks of ST and cigarettes, most will not consider trying to
switch, or will do so only reluctantly. A social and public
health environment that honestly informs smokers about
comparative risks would provide many more smokers
with the opportunity to lead longer and healthier lives.
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